( October 23, 2024, 8:33 AM EDT) -- LOS ANGELES — Partly granting a biotechnology firm’s motion to dismiss a rival’s counterclaims against it in a dispute over stem cell therapy patents, a California federal judge found that two noninfringement claims failed to identify the relevant products or plead sufficient facts....